These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 9428590)

  • 1. Evaluation of the antimeningococcal immunoglobin activity against five strains of Neisseria meningitidis group B from Latin America using mice as model.
    Perez-Ramirez PJ; Infante Bourzac JF; Sifontes Rodriguez S; Caro Azoy E; Balboa Gonzalez J; Sierra Gonzalez G; Campa Huergo C; Capo de Paz V
    Arch Med Res; 1997; 28(4):591-5. PubMed ID: 9428590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The hyperferremic mouse model for the evaluation of the effectiveness of VA-MENGOC-BC against Neisseria meningitidis B clinical isolates.
    Sifontes S; Infante JF; Pérez P; Caro E; Sierra G; Campa C
    Arch Med Res; 1997; 28(1):41-5. PubMed ID: 9078586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outer membrane vesicles (OMVs) and detoxified lipooligosaccharide (dLOS) obtained from Brazilian prevalent N. meningitidis serogroup B strains protect mice against homologous and heterologous meningococcal infection and septic shock.
    Jessouroun E; da Silveira IF; Larangeira AP; Pereira S; Fernandes SA; Rabinovitch L; Frasch CE; Castro-Faria-Neto HC; Bozza PT
    Vaccine; 2004 Jun; 22(20):2617-25. PubMed ID: 15193387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polyvalent 23 epitope polysaccharide pneumonia vaccine induced effective protection through strain-adapted effector mechanisms as demonstrated by the different cytokine responses in mice challenged with two different strains of Streptococcus pneumoniae.
    Mohler J; Moine P; Azoulay-Dupuis E; Henin D; Fantin B
    Eur Cytokine Netw; 2007 Mar; 18(1):23-30. PubMed ID: 17400535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the efficacy of human antimeningococcal immunoglobulin G in infant rats experimentally infected with Neisseria meningitidis group B.
    Infante JF; Marrero O; Sifontes S; Sierra G; Campa C; Caro E; Gutiérrez M; Malberti A; Capó V; Fariñas M
    Arch Med Res; 1994; 25(4):455-61. PubMed ID: 7858407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunogenecity induced by the VA-MENGOC-BC antimeningococcal vaccine against the ATCC C11. N. meningitidis strain in adolescents 12 years after being vaccinated].
    Camaraza MA; Ochoa R; Arnet AG; Sotolongo F; Martínez I; Cuevas I; Hernández D
    Rev Cubana Med Trop; 2004; 56(1):26-30. PubMed ID: 15849905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate.
    Delgado M; Yero D; Niebla O; González S; Climent Y; Pérez Y; Cobas K; Caballero E; García D; Pajón R
    Vaccine; 2007 Dec; 25(50):8420-31. PubMed ID: 17996338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization of mice with Neisseria meningitidis serogroup B genomic expression libraries elicits functional antibodies and reduces the level of bacteremia in an infant rat infection model.
    Yero CD; Pajón FR; Caballero ME; Cobas AK; López HY; Fariñas MM; Gonzáles BS; Acosta DA
    Vaccine; 2005 Jan; 23(7):932-9. PubMed ID: 15603895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization with meningococcal outer-membrane protein vesicles containing lipooligosaccharide protects mice against lethal experimental group B Neisseria meningitidis infection and septic shock.
    Quakyi EK; Frasch CE; Buller N; Tsai CM
    J Infect Dis; 1999 Sep; 180(3):747-54. PubMed ID: 10438363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of meningococcal PBP2 during natural infection and protective activity of anti-PBP2 antibodies against meningococcal bacteraemia in mice.
    Zarantonelli ML; Antignac A; Lancellotti M; Guiyoule A; Alonso JM; Taha MK
    J Antimicrob Chemother; 2006 May; 57(5):924-30. PubMed ID: 16513914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal immunization of mice with recombinant lipidated P2086 protein reduces nasal colonization of group B Neisseria meningitidis.
    Zhu D; Barniak V; Zhang Y; Green B; Zlotnick G
    Vaccine; 2006 Jun; 24(26):5420-5. PubMed ID: 16621173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A neonatal mouse model of meningococcal disease.
    Salit IE; Tomalty L
    Clin Invest Med; 1986; 9(2):119-23. PubMed ID: 3089662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Passive protection in the infant rat protection assay by sera taken before and after vaccination of teenagers with serogroup B meningococcal outer membrane vesicle vaccines.
    Toropainen M; Saarinen L; Wedege E; Bolstad K; Mäkelä PH; Käyhty H
    Vaccine; 2005 Sep; 23(40):4821-33. PubMed ID: 15970361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serogroup B meningococcal vaccines.
    Zimmer SM; Stephens DS
    Curr Opin Investig Drugs; 2006 Aug; 7(8):733-9. PubMed ID: 16955685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dynamics of cytokine d nitric oxide secretion in mice injected with Tityus serrulatus scorpion venom.
    Petricevich VL; Peña CF
    Mediators Inflamm; 2002 Jun; 11(3):173-80. PubMed ID: 12137246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: developmental chemistry and investigation of immunological responses following immunization of mice and rabbits.
    Cox AD; Zou W; Gidney MA; Lacelle S; Plested JS; Makepeace K; Wright JC; Coull PA; Moxon ER; Richards JC
    Vaccine; 2005 Oct; 23(43):5045-54. PubMed ID: 16046037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity.
    Welsch JA; Moe GR; Rossi R; Adu-Bobie J; Rappuoli R; Granoff DM
    J Infect Dis; 2003 Dec; 188(11):1730-40. PubMed ID: 14639545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.